Evolus’ (EOLS) “Buy” Rating Reaffirmed at HC Wainwright

Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $27.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 105.64% from the company’s previous close.

Several other analysts also recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price target on shares of Evolus in a research note on Wednesday. Barclays upgraded shares of Evolus from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $10.00 to $16.00 in a research note on Monday, January 29th.

Evolus Stock Performance

NASDAQ EOLS opened at $13.13 on Wednesday. The stock has a market cap of $821.86 million, a price-to-earnings ratio of -12.05 and a beta of 1.47. The business has a 50 day simple moving average of $13.21 and a 200 day simple moving average of $11.54. Evolus has a 52-week low of $7.07 and a 52-week high of $15.43.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The firm had revenue of $61.00 million for the quarter, compared to the consensus estimate of $61.14 million. On average, analysts predict that Evolus will post -0.51 EPS for the current year.

Insider Transactions at Evolus

In related news, insider David Moatazedi sold 7,706 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $13.08, for a total value of $100,794.48. Following the sale, the insider now owns 792,416 shares in the company, valued at approximately $10,364,801.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Evolus news, insider David Moatazedi sold 7,706 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $13.08, for a total value of $100,794.48. Following the transaction, the insider now directly owns 792,416 shares in the company, valued at $10,364,801.28. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Rui Avelar sold 27,603 shares of Evolus stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total transaction of $384,233.76. Following the sale, the insider now directly owns 372,288 shares of the company’s stock, valued at approximately $5,182,248.96. The disclosure for this sale can be found here. In the last three months, insiders sold 49,038 shares of company stock worth $674,232. 5.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Evolus

A number of large investors have recently made changes to their positions in EOLS. SG Americas Securities LLC acquired a new stake in Evolus during the 3rd quarter worth approximately $171,000. Bank of New York Mellon Corp increased its position in Evolus by 12.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 164,020 shares of the company’s stock worth $1,499,000 after buying an additional 17,999 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Evolus by 13.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 12,345 shares of the company’s stock worth $113,000 after buying an additional 1,484 shares in the last quarter. Rice Hall James & Associates LLC boosted its position in shares of Evolus by 61.7% in the third quarter. Rice Hall James & Associates LLC now owns 1,105,159 shares of the company’s stock valued at $10,101,000 after acquiring an additional 421,890 shares during the period. Finally, Black Swift Group LLC acquired a new position in shares of Evolus in the third quarter valued at about $466,000. Institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.